Practice Guidelines Fail – Again!
By Richard Amerling, M.D., Yet another expensive drug has been withdrawn from the market, even though it was “recommended” in a prestigious “practice guideline.” This month’s casualty is Eli Lilly’s Xigris (drotrecogin alfa). A large […]



